Royce & Associates LP decreased its stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 41.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 182,184 shares of the company's stock after selling 130,000 shares during the period. Royce & Associates LP owned 0.08% of Cellebrite DI worth $3,540,000 at the end of the most recent reporting period.
Other hedge funds also recently added to or reduced their stakes in the company. Catalyst Capital Advisors LLC acquired a new stake in shares of Cellebrite DI during the first quarter valued at approximately $51,000. Gen Wealth Partners Inc acquired a new stake in Cellebrite DI in the 4th quarter valued at approximately $85,000. NewEdge Advisors LLC grew its stake in shares of Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock worth $86,000 after acquiring an additional 3,352 shares during the last quarter. Sigma Planning Corp acquired a new stake in Cellebrite DI in the 1st quarter worth $233,000. Finally, HighTower Advisors LLC acquired a new stake in Cellebrite DI in the 4th quarter worth $274,000. 45.88% of the stock is currently owned by institutional investors.
Cellebrite DI Stock Performance
NASDAQ:CLBT traded down $0.08 during mid-day trading on Thursday, hitting $14.18. The company had a trading volume of 271,861 shares, compared to its average volume of 1,563,656. The firm has a market cap of $3.39 billion, a P/E ratio of -14.77, a P/E/G ratio of 2.92 and a beta of 1.28. The business's fifty day moving average is $15.64 and its two-hundred day moving average is $18.57. Cellebrite DI Ltd. has a fifty-two week low of $11.90 and a fifty-two week high of $26.30.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. Cellebrite DI had a positive return on equity of 35.36% and a negative net margin of 46.34%. The company had revenue of $107.55 million for the quarter, compared to analyst estimates of $109.36 million. During the same quarter last year, the firm posted $0.08 earnings per share. Cellebrite DI's revenue was up 20.0% compared to the same quarter last year. Equities analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.
Analyst Ratings Changes
Several analysts have issued reports on CLBT shares. JPMorgan Chase & Co. decreased their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research report on Monday, May 12th. Needham & Company LLC reiterated a "buy" rating and set a $24.00 target price on shares of Cellebrite DI in a research report on Friday, June 6th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $22.43.
Check Out Our Latest Stock Analysis on Cellebrite DI
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Stories
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
